» Articles » PMID: 35487976

OLFM4 Deficiency Delays the Progression of Colitis to Colorectal Cancer by Abrogating PMN-MDSCs Recruitment

Overview
Journal Oncogene
Date 2022 Apr 29
PMID 35487976
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic inflammatory bowel disease (IBD) is strongly associated with the development of colitis-associated tumorigenesis (CAT). Despite recent advances in the understanding of polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC) responses in cancer, the mechanisms of these cells during this process remain largely uncharacterized. Here, we discovered a glycoprotein, olfactomedin-4 (OLFM4), was highly expressed in PMN-MDSCs from colitis to colorectal cancer (CRC), and its expression level and PMN-MDSC population positively correlated with the progression of IBD to CRC. Moreover, mice lacking OLFM4 in myeloid cells showed poor recruitment of PMN-MDSCs, impaired intestinal homeostasis, and delayed development from IBD to CRC, and increased response to anti-PD1 therapy. The main mechanism of OLFM4-mediated PMN-MDSC activity involved the NF-κB/PTGS2 pathway, through the binding of LGALS3, a galactoside-binding protein expressed on PMN-MDSCs. Our results showed that the OLFM4/NF-κB/PTGS2 pathway promoted PMN-MDSC recruitment, which played an essential role in the maintenance of intestinal homeostasis, but showed resistance to anti-PD1 therapy in CRC.

Citing Articles

The Recruitment and Immune Suppression Mechanisms of Myeloid-Derived Suppressor Cells and Their Impact on Bone Metastatic Cancer.

Li C, Xue Y, Yinwang E, Ye Z Cancer Rep (Hoboken). 2025; 8(2):e70044.

PMID: 39947253 PMC: 11825175. DOI: 10.1002/cnr2.70044.


Intestinal metaplasia key molecules and UPP1 activation via Helicobacter pylori /NF-kB: drivers of malignant progression in gastric cancer.

Chen X, Zhou B, Wang S, Jiang X, Ping Y, Xia J Cancer Cell Int. 2024; 24(1):399.

PMID: 39695769 PMC: 11657005. DOI: 10.1186/s12935-024-03598-6.


OLFM4 modulates intestinal inflammation by promoting IL-22ILC3 in the gut.

Xing Z, Li X, He J, Chen Y, Zhu L, Zhang X Commun Biol. 2024; 7(1):914.

PMID: 39075283 PMC: 11286877. DOI: 10.1038/s42003-024-06601-y.


Targeting polymorphonuclear myeloid-derived suppressor cells in the immunosuppressive tumor microenvironment for cancer immunotherapy.

Li S, Long X MedComm (2020). 2024; 5(7):e602.

PMID: 38911064 PMC: 11193132. DOI: 10.1002/mco2.602.


Role played by MDSC in colitis-associated colorectal cancer and potential therapeutic strategies.

Wang K, Wang Y, Yin K J Cancer Res Clin Oncol. 2024; 150(5):243.

PMID: 38717677 PMC: 11078801. DOI: 10.1007/s00432-024-05755-w.


References
1.
Benson A, Venook A, Al-Hawary M, Cederquist L, Chen Y, Ciombor K . NCCN Guidelines Insights: Colon Cancer, Version 2.2018. J Natl Compr Canc Netw. 2018; 16(4):359-369. PMC: 10184502. DOI: 10.6004/jnccn.2018.0021. View

2.
Messersmith W . NCCN Guidelines Updates: Management of Metastatic Colorectal Cancer. J Natl Compr Canc Netw. 2019; 17(5.5):599-601. DOI: 10.6004/jnccn.2019.5014. View

3.
Vuik F, Nieuwenburg S, Bardou M, Lansdorp-Vogelaar I, Dinis-Ribeiro M, Bento M . Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. Gut. 2019; 68(10):1820-1826. PMC: 6839794. DOI: 10.1136/gutjnl-2018-317592. View

4.
Liao W, Overman M, Boutin A, Shang X, Zhao D, Dey P . KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. Cancer Cell. 2019; 35(4):559-572.e7. PMC: 6467776. DOI: 10.1016/j.ccell.2019.02.008. View

5.
Kajino-Sakamoto R, Fujishita T, Taketo M, Aoki M . Synthetic lethality between MyD88 loss and mutations in Wnt/β-catenin pathway in intestinal tumor epithelial cells. Oncogene. 2020; 40(2):408-420. DOI: 10.1038/s41388-020-01541-3. View